Adicet Bio (NASDAQ:ACET) reported quarterly losses of $(0.44) per share. This is a 84.51 percent increase over losses of $(2.84) per share from the same period last year.
SELLAS Life Sciences Launches Expanded Access Program For Galinpepimut-S
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of
